The role of financial factors in acceptance of clinical BRCA genetic testing

Genetic Testing

Volumn 11, Issue 1, 2007, Pages 101-110

  Kieran, Shannon ^a   Loescher, Lois J ^b   Lim, Kyung Hee ^c  

^a Bay Area Gynecology Oncology Regional Tumor Risk Program   (United States)

^b UNIVERSITY OF ARIZONA   (United States)

^c UNIVERSITY OF ARIZONA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; BREAST CANCER; CANCER RISK; COST CONTROL; ECONOMIC ASPECT; FEMALE; FINANCIAL MANAGEMENT; GENETIC ANALYSIS; GENETIC COUNSELING; GENETIC SCREENING; HEALTH INSURANCE; HUMAN; MAJOR CLINICAL STUDY; ONCOGENE; OVARY CANCER; PREDICTION; RISK ASSESSMENT; RISK FACTOR; TUMOR SUPPRESSOR GENE;

COSTS AND COST ANALYSIS; FEMALE; GENES, BRCA1; GENES, BRCA2; GENETIC SCREENING; HUMANS; MIDDLE AGED;

EID: 34147142403     PISSN: 10906576     EISSN: None     Source Type: Journal    
DOI: 10.1089/gte.2006.9999     Document Type: Article

References (40)

1. Armstrong K, Calzone K, Stopfer J, Fitzgerald G, Coyne J, Weber B (2000) Factors associated with decisions about clinical BRCA1/2 testing. Cancer Epidemiol Biomarkers Prev 9:1251-1254.
2. Armstrong K, Micco E, Carney A, Stopfer J, Pun M (2005) Racial differences in the use of BRCA1/2 testing among women with a family history of breast or ovarian cancer. J Am Med Assn 293: 1729-1736.
3. ASCO (1996) Statement of the American Society of Clinical Oncology: genetic testing for cancer susceptibility. J Clin Oncol 14:1730-1736: discussion 1737-1740.
4. ASCO (2003) American Society of Clinical Oncology policy statement update: genetic testing for cancer susceptibility. J Clin Oncol 21:2397-2406.
5. ASHG (1994) Statement of the American Society of Human Genetics on genetic testing for breast and ovarian cancer predisposition. Am J Hum Genet 55:i-iv.
6. Balmana J, Sanz J, Bonfill X, Casado A, Rue M, Gich I, Diez O, Sabate JM, Baiget M, Alonso MC (2004) Genetic counseling program in familial breast cancer: analysis of its effectiveness, cost and cost-effectiveness ratio. Int J Cancer 112:647-652.
7. Brooks L, Lennard F, Shenton A, Lalloo F, Ambus I, Ardent-Jones A, Belk R, Kerr B, Craufurd D, Ecles R, Gareth Evans D (2004) BRCA1/2 predictive testing: a study of uptake in two centers. Eur J Hum Genet 12:654-662.
8. Burke W, Daly M, Garber J, Botkin J, Kahn MJ, Lynch P, McTiernan A, Offit K, Perlman J, Petersen G, Thomson E, Varricchio C (1997) Recommendations for follow-up care of individuals with an inherited predisposition to cancer. II. BRCA1 and BRCA2. Cancer Genetics Studies Consortium. J Am Med Assn 277:997-1003.
9. Campbell MJ, Waters WE (1990) Does anonymity increase response rate in postal questionnaire surveys about sensitive subjects? A randomized trial. J Epidemiol Community Health 44:75-76.
10. Cappelli M, Surh L, Humphreys L, Verma S, Logan D, Hunter A, Allanson J (1999) Psychological and social determinants of women's decisions to undergo genetic counseling and testing for breast cancer. Clin Genet 55:419-430.
11. Chaliki H, Loader S, Levenkron JC, Logan-Young W, Hall WJ, Rowley PT (1995) Women's receptivity to testing for a genetic susceptibility to breast cancer. Am J Public Health 85:1133-1135.
12. Cohen D, Barton G, Gray J, Brain K (2004) Health economics and genetic service development: a familial cancer genetic example. Fam Cancer 3:61-67.
13. Collins FS (1996) BRCA1-lots of mutations, lots of dilemmas. N Engl J Med 334:186-188.
14. Croyle RT, Achilles JS, Lerman C (1997a) Psychologic aspects of cancer genetic testing: a research update for clinicians. Cancer 80: 569-575.
15. Croyle RT, Smith KR, Botkin JR, Bitty B, Nash J (1997b) Psychological responses to BRCA1 mutation testing: preliminary findings. Health Psychol 16:63-72.
16. Duly PA (2004) Hereditary cancer: guidelines in clinical practice-general overview. Ann Oncol 15(Suppl 4):iv121-125.
17. DNAdirect (2005) Hereditary breast and ovarian cancer, at: http://www. dnadirect.com/tests/breast_cancer/index.jsp/.
18. Edwards A, FJwyn G, Mulley A (2002) Explaining risks: turning numerical data into meaningful pictures. Br Med J 324:827-830.
19. Fasouliotis SJ, Schenker JG (2000) BRCA1 and BRCA2 gene mutations: decision-making dilemmas concerning testing and management. Obstel Gynecol Surv 55:373-384.
20. Foster C, Evans DG, Eeles R, Eccles D, Ashley S, Brooks E, Cole T, Cook J, Davidson R, Gregory H, Mackay J, Morrison PJ, Watson M (2004) Non-uptake of predictive genetic testing for BRCA 1/2 among relatives of known carriers: attributes, cancer worry, and barriers to testing in a multicenter clinical cohort. Genet Test 8:23-29.
21. Geller G, Botkin JR, Green MJ, Press N, Biesecker BB, Wilfond B, Grana G, Daly MB, Schneider K, Kahn MJ (1997) Genetic testing for susceptibility to adult-onset cancer. The process and content of informed consent. J Am Med Assn 277:1467-1474.
22. Hall MA, Rich SS (2000) Patients' fear of genetic discrimination by health insurers: the impact of legal protections. Genet Med 2:214-221.
23. Hall JM, Ece MK, Newman B, Morrow JE, Anderson EA, Huey B, King MC (1990) Linkage of early-onset familial breast cancer to chromosome 17q21. Science 250:1684-1689.
24. Hallowell N, Murton F (1998) The value of written summaries of genetic consultations. Patient Educ Couns 35:27-34.
25. Katz A (2006) Health Net OKs covering gene tests. New Haven Register. New Haven, CT.
26. Kanff ND, Scheuer L, Robson MB, Glogowski E, Kelly B, Barakat R, Heerdt A, Borgen PI, Davis JG, Offit K (2001) Insurance reimbursement for risk-reducing mastectomy and oophorectomy in women with BRCA1 or BRCA2 mutations. Genet Med 3:422-425.
27. Lawrence WF, Peshkin BN, Liang W, Isaacs C, Lerman C. Mandelblatt JS (2001) Cost of genetic counseling and testing for BRCAl and BRCA2 breast cancer susceptibility mutations. Cancer Epidemiol Biomarkers Prev 10:475-481.
28. Lee SC, Bernhardt BA, Helzlsouer KJ (2002) Utilization of BRCA 1/2 genetic testing in the clinical setting: report from a single institution. Cancer 94:1876-1885.
29. Lerman C, Scay J, Balshem A, Audrain J (1995) Interest in genetic testing among first-degree relatives of breast cancer patients. Am J Med Genet 57:385-392.
30. Lodder L, Frets PG, Trijsburg RW, Klijn JG, Seynaeve C, Tilanus MM, Bartels CC, Meijers-Heijboer EJ, Verhoog EC, Niermeijer MF (2003) Altitudes and distress levels in women at risk to carry a BRCA1/BRCA2 gene mutation who decline genetic testing. Am J Med Genet A 119:266-272.
31. Lynch MT, Watson P, Tinley S, Snyder C, Durham C, Lynch J, Kiruarsky Y, Serova O, Ecnoir G, Lerman C, Narod SA (1999) An update on DNA-based BRCA1/BRCA2 genetic counseling in hereditary breast cancer. Cancer Genet Cytogenet 109:91-98.
32. Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S, Liu Q, Cochran C, Bennett LM, Ding W, et al. (1994) A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 266:66-71.
33. Myriad (2005). Myriad Genetics. Inc., Salt Lake City UT, personal communication.
34. NCCN (2006) Practice Guidelines in Oncology: Hereditary Breast &/or Ovarian Cancer. National Comprehensive Cancer Network. http://www.nccn.org/ professionals/physician_gls/PDF/genetics_screening. pdf/.
35. NCSL (2006) Genetics Laws and Legislative Activity. National Conference of State Legislatures. http://www.ncsl.org/programs/health/Genetics/charts.htm/.
36. Peterson EA, Milliron KJ, Lewis KE, Goold SD, Merajver SD (2002) Health insurance and discrimination concerns and BRCA 1/2 testing in a clinic population. Cancer Epidemiol Biomarkers Prev 11:79-87.
37. Schoonmaker MM, Bernhardt BA, Holtzman NA (2000) Factors influencing health insurers' decisions to cover new genetic technologies. Int J Technol Assess Health Care 16:178-189.
38. Smith RA, Saslow D, Sawyer KA, Burke W, Costanza ME, Evans WP, 3rd, Foster RS, Jr., Hendrick E, Eyre HJ, Sener S (2003) American Cancer Society guidelines for breast cancer screening: update 2003. CA Cancer J Clin 53:141-169.
39. Struewing JP, Lerman C, Kase RG, Giambarresi TR, Tucker MA (1995) Anticipated uptake and impact of genetic testing in hereditary breast and ovarian cancer families. Cancer Epidemiol Biomarkers Prev 4:169-173.
40. USPTSF (2005) Genetic risk assessment und BRCA mutation testing for breast and ovarian cancer susceptibility: recommendation statement. Ann Intern Med 143:355-361.